JUMP REPORT
Avg Daily Volume: 624,861 Market Cap: 8.26B
Sector: Technology Short Interest: 3.73
EARNINGS EXPECTATIONS:
THIS QTR: EPS: 2.43/share REV: 565.9/M
___________________________________________________________
LAST QTR: EPS: 2.55/share ACTUAL: 2.59/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: 2.49/share REV: 570.8/M
______________________________________________________
FULL YR: EPS: 10.55/share REV: 2,730/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
______________________________________________________
BEAT/MISS RECORD: 67% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 10.67, -4.27, -5.02
EXPECTED JUMP MOVE: 8%
Links To Latest News and Headlines
From commerce to culture, software is digitizing every aspect of our lives. In the past, the undeniable tailwinds fueling SaaS companies led to lofty valuation multiples that made it easier to raise capital. But this was a double-edged sword as the high prices exposed them to big drawdowns, and unfortunately, the industry has tumbled by 9.8% over the last six months. This performance is a noticeable divergence from the S&P 500’s 8.4% return.
Recent performance snapshot F5 (FFIV) has drawn attention after recent trading, with the stock last closing at $395.23. Investors are weighing this price against the company’s value score of 3 and its current fundamentals. See our latest analysis for F5. While the share price slipped 0.2% over the last trading day and 3.4% over the past week, F5’s 30 day share price return of 11.6% and year to date gain of 54.0% suggest momentum has been building alongside a 34.6% 1 year total shareholder…
F5 (FFIV) is positioned for a potentially extended growth cycle, driven by a “refresh plus” dynamic
SEATTLE, June 09, 2026–F5 (NASDAQ: FFIV), the global leader in delivering and securing every app and API, today announced new web application and API protection (WAAP) capabilities for its Application Delivery and Security Platform designed to keep enterprises ahead of a rapidly shifting threat landscape. Frontier AI models have collapsed the window between vulnerability discovery and active exploitation, giving threat actors faster, cheaper, and more available means of attack. F5 has expanded
DOCU vs. FFIV: Which Stock Is the Better Value Option?
StockJumpers analysis and trade plans are uploaded generally 1 HOUR (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is striped down to only what it needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.